News | July 06, 2022
Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Younger Indians have a 10 times higher rate of heart attack
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
_256_384.jpg){kind=logo}
Meets the growing need for US-based API solubility and bioavailability enhancement services
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Subscribe To Our Newsletter & Stay Updated
